
Dynavax Technologies (DVAX) Stock Forecast & Price Target
Dynavax Technologies (DVAX) Analyst Ratings
Bulls say
Dynavax Technologies Corp demonstrates strong potential due to the promising vaccine response rates (VRR) of its 100ug dose, which are comparable to the established Shingrix vaccine, paired with significantly better tolerability. Furthermore, the company shows encouraging results in CD4+ T-cell responses for its Z-1018 shingles vaccine candidate, indicating robust immunogenicity and safety profiles that align with management's objectives. This positive data from Dynavax's ongoing product development and pipeline enhancements strengthens the outlook for the company's future revenue generation from its vaccine portfolio, primarily driven by CpG 1018 and HEPLISAV-B.
Bears say
Dynavax Technologies Corp faces significant risks in its clinical development pipeline, with the potential for future candidates to fail efficacy endpoints or present safety concerns that could hinder approvals and commercialization. The company may struggle to effectively bring its proprietary candidates to market due to unfavorable market conditions, strong competition, and internal challenges, which could further exacerbate revenue generation issues. Additionally, the uncertainty surrounding potential partnerships for its candidates adds another layer of risk, as unsuccessful negotiations could jeopardize the success of their commercial launches.
This aggregate rating is based on analysts' research of Dynavax Technologies and is not a guaranteed prediction by Public.com or investment advice.
Dynavax Technologies (DVAX) Analyst Forecast & Price Prediction
Start investing in Dynavax Technologies (DVAX)
Order type
Buy in
Order amount
Est. shares
0 shares